LUPIN PHARMS FDA Approval NDA 212303

NDA 212303

LUPIN PHARMS

FDA Drug Application

Application #212303

Documents

Letter2021-06-29

Application Sponsors

NDA 212303LUPIN PHARMS

Marketing Status

None (Tentative Approval)001

Application Products

001TABLET; ORAL50MG; 300MG; 300MG0Dolutegravir, Lamivudine, and Tenofovir Disoproxil FumarateDolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate

FDA Submissions

TYPE 4; Type 4 - New CombinationORIG1TA2021-06-25STANDARD

Submissions Property Types

ORIG1Null6

CDER Filings

LUPIN PHARMS
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 212303
            [companyName] => LUPIN PHARMS
            [docInserts] => ["",""]
            [products] => [{"drugName":"Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate","activeIngredients":"Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate","strength":"50MG; 300MG; 300MG","dosageForm":"TABLET; ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
            [labels] => 
            [originalApprovals] => [{"actionDate":"06\/25\/2021","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2021\\\/212303Orig1s000TAltr.pdf\"}]","notes":"> Label is not available on this site."}]
            [supplements] => 
            [actionDate] => 2021-06-25
        )

)

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.